Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jan 12;12(1):169.
doi: 10.3390/biomedicines12010169.

Pulmonary Hypertension and the Gut Microbiome

Thomas Mason  1 , Bhashkar Mukherjee  1   2 , Philip Marino  1
Affiliations
Review

Pulmonary Hypertension and the Gut Microbiome

Thomas Mason et al. Biomedicines. .

Abstract

The gut microbiome and its associated metabolites are integral to the maintenance of gut integrity and function. There is increasing evidence that its alteration, referred to as dysbiosis, is involved in the development of a systemic conditions such as cardiovascular disease (e.g., systemic hypertension, atherosclerosis). Pulmonary hypertension (PH) is a condition characterised by progressive remodelling and vasoconstriction of the pulmonary circulation, ultimately leading to right ventricular failure and premature mortality if untreated. Initial studies have suggested a possible association between dysbiosis of the microbiome and the development of PH. The aim of this article is to review the current experimental and clinical data with respect to the potential interaction between the gut microbiome and the pathophysiology of pulmonary hypertension. It will also highlight possible new therapeutic targets that may provide future therapies.

Keywords: dysbiosis; gut microbiome; pulmonary hypertension.

PubMed Disclaimer

Conflict of interest statement

P. Marino has received honoraria and travel bursaries from MSD, GlaxoSmithKline, Actelion and Janssen Pharmaceuticals, as well as education, research and service development grants from Actelion and Janssen Pharmaceuticals. B. Mukherjee has no conflicts of interests or disclosures. T. Mason has no conflicts of interests or disclosures.

Figures

Figure 1
Figure 1
Schematic summarising the proposed interactions between the GM and the pathophysiology of PAH.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Humbert M., Kovacs G., Hoeper M.M., Badagliacca R., Berger R.M.F., Brida M., Carlsen J., Coats A.J.S., Escribano-Subias P., Ferrari P., et al. 2022 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. Eur. Heart J. 2022;43:3618–3731. doi: 10.1093/eurheartj/ehac237. - DOI - PubMed
    1. Eckburg P.B., Bik E.M., Bernstein C.N., Purdom E., Dethlefsen L., Sargent M., Gill S.R., Nelson K.E., Relman D.A. Diversity of the Human Intestinal Microbial Flora. Science. 2005;308:1635–1638. doi: 10.1126/science.1110591. - DOI - PMC - PubMed
    1. David L.A., Maurice C.F., Carmody R.N., Gootenberg D.B., Button J.E., Wolfe B.E., Ling A.V., Devlin A.S., Varma Y., Fischbach M.A., et al. Diet Rapidly and Reproducibly Alters the Human Gut Microbiome. Nature. 2014;505:559–563. doi: 10.1038/nature12820. - DOI - PMC - PubMed
    1. Zhernakova A., Kurilshikov A., Bonder M.J., Tigchelaar E.F., Schirmer M., Vatanen T., Mujagic Z., Vila A.V., Falony G., Vieira-Silva S., et al. Population-Based Metagenomics Analysis Reveals Markers for Gut Microbiome Composition and Diversity. Science. 2016;352:565–569. doi: 10.1126/science.aad3369. - DOI - PMC - PubMed
    1. Tousoulis D., Guzik T., Padro T., Duncker D.J., De Luca G., Eringa E., Vavlukis M., Antonopoulos A.S., Katsimichas T., Cenko E., et al. Mechanisms, Therapeutic Implications, and Methodological Challenges of Gut Microbiota and Cardiovascular Diseases: A Position Paper by the ESC Working Group on Coronary Pathophysiology and Microcirculation. Cardiovasc. Res. 2022;118:3171–3182. doi: 10.1093/cvr/cvac057. - DOI - PMC - PubMed

LinkOut - more resources